Hims & Hers Health Stock Is Tumbling Thursday: Here's Why
Hims & Hers Health Stock Is Tumbling Thursday: Here's Why
"FDA confirmed with the drug's manufacturer that their stated product availability and manufacturing capacity can meet the present and projected national demand. Patients and prescribers may still see intermittent localized supply disruptions as the products move through the supply chain from the manufacturer and distributors to local pharmacies," the FDA said.Hims & Hers Health Inc (NYSE:HIMS) shares are trading lower Thursday in possible sympathy with Eli Lilly And Co's (NYSE:LLY), after the U.S. Food and Drug Administration removed it from the weight-loss and diabetes drugs shortage list.
Hims & Hers Health Inc（紐交所：HIMS）股價週四低開，可能是出於對禮來公司（紐交所：LLY）的同情，此前美國食品和藥物管理局將禮來公司的減重和糖尿病藥物移出短缺清單。
What Happened: The FDA said in a statement late Wednesday that Eli Lilly's supply of Mounjaro, which is used to treat diabetes, and weight-loss drug Zepbound can now keep up with current demand.
事件經過：FDA週三晚間發佈聲明稱，禮來公司的治療糖尿病藥物Mounjaro和減重藥物Zepbound的供應現在可以滿足當前需求。
Mounjaro had been on the regulator's shortage list since late 2022, and Zepbound had been on the list since April.
Mounjaro自2022年底起被列入監管機構的短缺清單，Zepbound自4月起被列入清單。
"FDA confirmed with the drug's manufacturer that their stated product availability and manufacturing capacity can meet the present and projected national demand. Patients and prescribers may still see intermittent localized supply disruptions as the products move through the supply chain from the manufacturer and distributors to local pharmacies," the FDA said.
「FDA已與藥品生產商確認，他們所述的產品供應和製造能力可以滿足目前和未來的國家需求。患者和處方醫師可能仍會在產品從生產商和分銷商到當地藥店的供應鏈中移動時看到間歇性的局部供應中斷，」FDA表示。
Hims & Hers Health shares are under pressure on Thursday as the firm sells cheaper versions of the aforementioned drugs, known as compounded drugs. Hims & Hers said in May that it would begin selling compounded versions of GLP-1 injections. Shares surged on the news and have more than doubled since the start of the year.
Hims & Hers Health股價週四受到壓力，因爲該公司銷售所述藥物的更便宜版本，即混合藥物。Hims & Hers在5月表示將開始銷售GLP-1注射液的混合版本。股價在這一消息的刺激下飆升，自年初以來增長超過一倍。
Don't Miss: EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO
不要錯過：獨家：Tema etf首席執行官預測GLP-1減重藥物可能會成爲一個萬億美元的市場。
The limited supply for weight-loss and diabetes drugs from Lilly and rival Novo Nordisk A/S (NYSE:NVO) sparked a demand boom for compounded drugs, which are made by combining, mixing, or altering drug ingredients, per Reuters.
禮來和競爭對手諾和諾德（紐交所：NVO）的減重和糖尿病藥物供應有限引發了對混合藥物的需求激增，這些藥物是通過結合、混合或改變藥物成分製成的，據路透社報道。
The report also indicates that regulators allow compounded versions of drugs to enter the market to meet demand when there is a shortage. When there is no shortage, compounded drug makers are reportedly unable to make "regular or inordinate amounts" of the drugs.
該報告還顯示，監管機構允許混合藥物的版本進入市場，以滿足需求，當存在短缺時。當沒有短缺時，據報道，混合藥品製造商無法生產「正常或過量的」藥物。
Lilly reportedly began selling vials of its lowest dose of Zepbound in the U.S. directly to consumers via its website to help push back against the rise of compounded versions of the drug. Novo Nordisk's drugs were still listed on the FDA's shortage list as of Thursday.
據報道，禮來開始直接向美國消費者銷售其最低劑量的Zepbound小瓶，以幫助抵制藥物復配版本的崛起。 直至週四，諾和諾德的藥品仍然列在美國食品藥品監督管理局的短缺名單上。
HIMS Price Action: Hims & Hers Health shares were down 8.92% at $17.26 at the time of publication, according to Benzinga Pro.
HIMS股價走勢：據Benzinga Pro報道，截至發稿時，Hims & Hers Health股價下跌8.92%，報17.26美元。
Photo: Natalia Varlei from Shutterstock.
照片：來自shutterstock的Natalia Varlei。
